TARS

Tarsus Pharmaceuticals, Inc. Common Stock

72.59

USD

TARS Earnings Reports

Positive Surprise Ratio

TARS beat 15 of 22 last estimates.

68%

Next Report

Date of Next Report

Apr 29, 2026

Estimate for Q1 26 (Revenue/ EPS)

$156.82M

-$0.29

Implied change from Q4 25 (Revenue/ EPS)

+3.39%

+45.00%

Implied change from Q1 25 (Revenue/ EPS)

+100.19%

-54.69%

Tarsus Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Feb 23, 2026, TARS reported earnings of -0.20 USD per share (EPS) for Q4 25, missing the estimate of -0.09 USD, resulting in a -106.19% surprise. Revenue reached 151.67 million, compared to an expected 147.46 million, with a 2.86% difference. The market reacted with a +7.79% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.29 USD, with revenue projected to reach 156.82 million USD, implying an increase of 45.00% EPS, and increase of 3.39% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Pharvaris N.V. Ordinary Shares

Report Date

Apr 02, 2026 For Q4 25

Estimate

-$0.63

Actual

-$0.72

Surprise

-13.69%

Innate Pharma S.A. ADS

Report Date

Apr 01, 2026 For Q1 26

Estimate

-$0.12

Actual

-$0.55

Surprise

-353.80%

MiNK Therapeutics, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.83

Actual

-$0.55

Surprise

+33.64%

Kairos Pharma, Ltd.

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.07

Surprise

-28.68%

Imunon, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$1.19

Actual

-$1.99

Surprise

-66.18%

Soligenix, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.57

Actual

-$0.28

Surprise

+50.98%

Cadrenal Therapeutics, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$1.18

Actual

-$1.43

Surprise

-20.34%

BioAtla, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$12.24

Actual

-$8.00

Surprise

+34.64%

Sunshine Biopharma Inc.

Report Date

Apr 03, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.54

Surprise

-96.08%

CNS Pharmaceuticals, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$5.19

Actual

-$10.15

Surprise

-95.50%

FAQ

What were Tarsus Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Tarsus Pharmaceuticals, Inc. Common Stock reported EPS of -$0.20, missing estimates by -106.19%, and revenue of $151.67M, 2.86% above expectations.

How did the market react to Tarsus Pharmaceuticals, Inc. Common Stock's Q4 2025 earnings?

The stock price moved up 7.79%, changed from $69.59 before the earnings release to $75.01 the day after.

When is Tarsus Pharmaceuticals, Inc. Common Stock expected to report next?

The next earning report is scheduled for Apr 29, 2026.

What are the forecasts for Tarsus Pharmaceuticals, Inc. Common Stock's next earnings report?

Based on 7 analysts, Tarsus Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.29 and revenue of $156.82M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.